Ac Immune Sa

Genentech, Inc.

Katholieke Universiteit Leuven

Janssen Pharmaceuticals, Inc.

Genetech, Inc.

Viacord LLC

Viacell, Inc.

Katholieke Universiteit Leuven, K.u. Leuven Research & Development

Andreas Muhs

Andrea M Pfeifer

Maria Pihlgren

Ryan Jefferson Watts

Oskar Adolfsson

Maria Pihlgren Bosch

Fred Van Leuven

David T Hickman

Wolfgang Froestl

Marija Vukicevic Verhille

Charlotte Sadaka

Nicolas Piot

Elizabeth Anne Ramsburg

Saroj Raj Ghimire

Donata De Marco

Heiko Kroth

Jaap Goudsmit

Nampally Sreenivasachary

Pascal Benderitter

Cotinica Hamel

Kristin Ruth Wildsmith

Marcel Van Der Brug

Freddy Kamiel Van Leuven

Stephan Wnendt

Isidro Hotzel

Ruth Greferath

Chakkumkal Anish

Gai Ayalon

Danielle Marie Di Cara

Claude Nicolau

Maria Pilar Lopez-Deber

Pedro Reis

Sophie Lohmann

Maria Pilar Lopez Deber

Rime Madani

William Charles Mobley

Pavel Vasilyevich Belichenko

David Hickman

Methods for inducing anti-phosphorylated Tau antibodies without inducing a severe adverse event in humans are described. The methods include administering to the subject an effective amount of liposomes including a toll-like receptor 4 agonist and a Tau phosphopeptide presented on the surface of the liposome.

Method of safe administration of phosphorylated Tau peptide vaccine

Liposomes containing tau peptides, preferably phosphorylated tau peptides, and conjugates containing tau peptides, preferably phosphorylated tau peptides, conjugated to an immunogenic carrier are described. Pharmaceutical compositions and uses of the liposomes and/or conjugates for treating or preventing a neurodegenerative disease or disorder, such as Alzheimer's Disease, are also described.

Compositions of phosphorylated tau peptides and uses thereof

Method of safe administration of phosphorylated tau peptide vaccine

Methods for inducing an immune response against tau protein in a subject suffering from a neurodegenerative disease, disorder or condition, such as Alzheimer's Disease, are described. The methods include administering a liposomal priming composition containing tau peptides, preferably phosphorylated tau peptides, and a conjugate boosting composition containing tau peptides, preferably phosphorylated tau peptides, conjugated to an immunogenic carrier.

Heterologous administration of tau vaccines

The invention provides anti-Tau antibodies and methods of using the same.

Anti-tau antibodies and methods of use

Anti-Tau antibodies and methods of use

The present invention relates to novel compounds that can be employed in the treatment of a group of disorders and abnormalities associated with amyloid protein, such as Alzheimer's disease, and of diseases or conditions associated with amyloid-like proteins. The compounds of the present invention can also be used in the treatment of ocular diseases associated with pathological abnormalities/changes in the tissues of the visual system. The present invention further relates to pharmaceutical compositions comprising these compounds and to the use of these compounds for the preparation of medicaments for treating or preventing diseases or conditions associated with amyloid and/or amyloid-like proteins. A method of treating or preventing diseases or conditions associated with amyloid and/or amyloid-like proteins is also disclosed.

Compounds for the treatment of diseases associated with amyloid or amyloid-like proteins

The present invention relates to methods and compositions for the therapeutic and diagnostic use in the treatment of diseases and disorders which are caused by or associated with neurofibrillary tangles. In particular, the invention relates to antibodies, which specifically recognize and bind to phosphorylated pathological protein tau-conformers and to methods and compositions involving said antibodies for the therapeutic and diagnostic use in the treatment of tauopathies including Alzheimer's Disease (AD).

Methods of diagnosing tau-protein-associated disease

Methods of diagnosing diseases caused by or associated with neurofibrillary tangles by phosphospecific antibodies recognising Tau

The present invention relates to 2,6-diaminopyridine compounds that can be employed in the treatment of a group of disorders and abnormalities associated with amyloid protein and of diseases or conditions associated with amyloid-like proteins. The compounds of the present invention can also be used in the treatment of ocular diseases associated with pathological abnormalities/changes in the tissues of the visual system.

2,6-diaminopyridine compounds suitable for treating diseases associated with amyloid or amyloid-like proteins or for treating or preventing ocular diseases or conditions associated with a pathological abnormality/change in the tissue of the visual system

The present invention relates to method for preparing liposome-based constructs comprising a peptide, particularly an antigenic peptide, of interest modified through hydrophobic moieties reconstituted in liposomes and to the antigenic constructs obtained with said method. The invention further relates to the use of said constructs for the therapeutic and diagnostic use in the treatment of diseases and disorders, which are caused by or associated with proteopathy such as Alzheimer's Disease.

Method for preparing liposome-based constructs

The present invention provides methods and compositions for the therapeutic and diagnostic use in the treatment of diseases and disorders which are caused by or associated with neurofibrillary tangles. In particular, the invention relates to humanized antibodies, which specifically recognize and bind to phosphorylated pathological protein tau-conformers to methods and compositions involving said antibodies for the therapeutic and diagnostic use in the treatment of tauopathies including Alzheimer's Disease (AD).

Humanized tau antibody

The present invention relates to anti-Tau antibodies, such as antibodies that bind to a phosphorylated epitope on human Tau protein with high specificity and/or affinity, and methods of using the same.

The antibodies enabled by the teaching of the present invention are particularly useful for the treatment of diseases and disorders which are caused by or associated with amyloid or amyloid-like proteins including amyloidosis, a group of diseases and disorders associated with amyloid plaque formation including secondary amyloidosis and age-related amyloidosis including, but not limited to, neurological disorders such as Alzheimer's Disease (AD).

Polynucleotides encoding anti-amyloid beta monoclonal antibodies

Growing community of inventors

Pully, Switzerland

Andreas Muhs